Shao-Chin Chiang
Overview
Explore the profile of Shao-Chin Chiang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chueh C, Yu H, Wen Y, Shiu M, Chen Y, Chiang S, et al.
J Infect Public Health
. 2025 Feb;
18(4):102677.
PMID: 39893713
Background: Care retention and medication adherence are crucial for individuals living with human immunodeficiency virus (HIV). Discrepancies exist between real-world evidence and randomized trials regarding early antiretroviral therapy (ART) initiation...
2.
Hsu S, Chiang S, Hsu J, Ko Y
Clin Ther
. 2024 Dec;
47(2):e1-e4.
PMID: 39643453
Background: Breast cancer patients receiving chemotherapy may develop a serious complication called febrile neutropenia (FN). We aimed to validate and compare three existing FN prediction models for breast cancer patients...
3.
Tseng T, Chiang S, Hsu J, Ko Y
PLoS One
. 2024 Jun;
19(6):e0303294.
PMID: 38857244
Objectives: To examine the cost-effectiveness of using granulocyte colony-stimulating factor (G-CSF) for primary or secondary prophylaxis in patients with breast cancer from the perspective of Taiwan's National Health Insurance Administration....
4.
Al-Naqqash M, Castaneda-Hernandez G, Chiang S, Ibnshamsah F, Reinert T, Rifkin R, et al.
Future Oncol
. 2023 Nov;
20(9):481-491.
PMID: 38010143
The aim of this plain language review article is to help you to understand biosimilar medicines (called biosimilars) by giving a summary of biologic medicines and biosimilars. It is based...
5.
Hsu S, Chiang S, Hsu J, Ko Y
PLoS One
. 2023 Jul;
18(7):e0288642.
PMID: 37459309
Background And Objectives: Myelosuppressive chemotherapy is effective for breast cancer but carries a potential risk of febrile neutropenia (FN). Clinical practice guidelines have recommended prophylaxis with granulocyte colony-stimulating factor (G-CSF)...
6.
Liu Y, Huang H, Sheu S, Liu Y, Lee I, Chiang S, et al.
Exp Biol Med (Maywood)
. 2023 Jun;
248(7):656-664.
PMID: 37340785
Ellagic acid, the marker component of peels of L., is known traditionally to treat traumatic hemorrhage. In this study, the cellular mechanism underlying ellagic acid-induced anti-inflammation was investigated using lipopolysaccharides...
7.
Huang P, Poon S, Chang S, Kuo C, Chien M, Chen C, et al.
Int J Gen Med
. 2023 Jan;
16:211-220.
PMID: 36699342
Purpose: Medication reconciliation (MedRec) is a process to ensure complete and accurate communication of patient medication information throughout care transitions to prevent medication errors. Hospitals in Taiwan have stride to...
8.
Poon S, Hsu J, Ko Y, Chiang S
Healthcare (Basel)
. 2021 Nov;
9(11).
PMID: 34828645
Despite the first approval of biosimilars' in 2010, biosimilar products usage has remained low in Taiwan. This cross-sectional survey study assessed healthcare professionals' (HCPs)-hospital pharmacists, oncologists, and rheumatologists-knowledge, and attitudes...
9.
Chen H, Chen J, Chiang S, Lin Y, Ko Y
Medicine (Baltimore)
. 2021 Oct;
100(43):e27567.
PMID: 34713830
To determine the economic burden of metastatic breast cancer (MBC) in Taiwan, we conducted a national retrospective claim database analysis to evaluate the incremental healthcare costs and utilization of MBC...
10.
Chiang S, Shen M, Lin C, Chang H
PLoS One
. 2021 Sep;
16(9):e0257873.
PMID: 34582474
Closed-system drug transfer devices (CSTDs) are used to prevent occupational exposure to hazardous drugs in health care providers. They are considered Class II medical devices by the US FDA and...